AstraZeneca, Korea’s Hanmi Move To Appellate Court In Nexium Patent Dispute
This article was originally published in The Pink Sheet Daily
Executive Summary
A recent settlement agreement at the U.S. district court level does little to resolve a battle over AstraZeneca’s second best-selling drug. Hanmi says its position is on “solid ground,” but it remains unclear if it would pursue an at-risk launch if it receives final FDA approval.
You may also be interested in...
At-Risk Launches: Three Cases May Determine How Damages Are Calculated
How risky are at-risk launches of generic products?
Teva Could Face Damages Of $1.2 Billion For At-Risk Launch Of Generic Protonix
A jury finds that Pfizer's patent on the proton pump inhibitor is valid; analyst Timothy Anderson estimates that without a settlement Teva's damages could top $1 billion but thinks the actual impact will be smaller.
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.